Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations
1 other identifier
expanded_access
N/A
0 countries
N/A
Brief Summary
Basilea provided expanded access to derazantinib for patients with locally advanced, inoperable or metastatic intrahepatic cholangiocarcinoma (iCCA) with FGFR genomic alterations on a patient by patient basis while clinical development of derazantinib was ongoing.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 11, 2019
CompletedFirst Posted
Study publicly available on registry
September 12, 2019
CompletedApril 6, 2025
April 1, 2025
September 11, 2019
April 3, 2025
Conditions
Keywords
Interventions
derazantinib will be administered orally
Eligibility Criteria
You may qualify if:
- all other treatment options had been exhausted
- patient was ineligible for any ongoing trials or was geographically inaccessible to trials including a trial with derazantinib
- there was a reason to believe that the potential benefit of receiving derazantinib outweighs the risk of treatment with an investigational drug product
- patient was willing and able to provide written informed consent
- if applicable, regulatory approval by the appropriate jurisdiction was obtained
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Manuel Häckl, MD
Basilea Pharmaceutica International Ltd
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 11, 2019
First Posted
September 12, 2019
Last Updated
April 6, 2025
Record last verified: 2025-04